Piper Sandler analyst Edward Tenthoff reiterated a Buy rating on Milestone Pharmaceuticals (MIST – Research Report) today and set a price target of $12.00. The company’s shares closed yesterday at $3.30.
According to TipRanks, Tenthoff is a 5-star analyst with an average return of 11.8% and a 39.68% success rate. Tenthoff covers the Healthcare sector, focusing on stocks such as Arrowhead Pharmaceuticals, Cue Biopharma, and Aptose Biosciences.
Currently, the analyst consensus on Milestone Pharmaceuticals is a Strong Buy with an average price target of $14.20.
See today’s best-performing stocks on TipRanks >>
Based on Milestone Pharmaceuticals’ latest earnings release for the quarter ending June 30, the company reported a quarterly GAAP net loss of $16.04 million. In comparison, last year the company had a GAAP net loss of $16.65 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Milestone Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of novel small molecule therapeutics based on clinically-validated mechanisms for the treatment of cardiovascular diseases. It designs and develops a rapid-onset nasal spray with Etripamil. The company was founded by Philippe Douville and Philippe Lamarre in 2005 and is headquartered in Montreal, Canada.
Read More on MIST:
- Milestone Pharmaceuticals reports Q2 EPS (37c), consensus (39c)
- Milestone Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Clinical and Corporate Update
- 2 ‘Strong Buy’ Penny Stocks That Could Rally All the Way to $10 (or More)
- Milestone Pharmaceuticals announces publication of results from Phase 3 RAPID
- Milestone Pharmaceuticals assumed at Hold from Buy at Jefferies
